

90

87.

The vaccine of claim 85 further comprising an adjuvant.

91

88.

The vaccine of claim 86 further comprising an adjuvant.

**REMARKS**

The present Preliminary Amendment is submitted to add claims to combinations of antibodies that were not submitted with the application as filed. Support for the present Preliminary Amendment can be found in Figure 22 of the application.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "Version with Markings to Show Changes Made."

Respectfully submitted,

Dated: February 11, 2002

*Karoline K. M. Shair*

Karoline K. M. Shair, Ph.D.

Reg. No.: 44,332 *for*

Brenda Hershbach Jarrell, Ph.D.

Reg. No.: 39,223

CHOATE, HALL & STEWART  
Exchange Place  
53 State Street  
Boston, Massachusetts 02109  
Tel: (617) 248-5000  
Fax: (617) 248-4000

**Version with Markings Showing Changes Made**

**In the Claims:**

Claims 72-88 have been added.

- 72. A combination of two or more antibodies directed to one or more conformational epitopes of E2 protein of Hepatitis C virus.
73. The combination of two or more antibodies of claim 72, wherein the combination results in increased binding of the antibodies to one or more conformational epitopes of E2 protein of Hepatitis C virus.
74. The combination of two or more antibodies of claim 73, wherein the increased binding of two or more antibodies to the one or more conformational epitopes of E2 protein of Hepatitis C virus is greater than 100% relative to the binding of a single antibody.
75. The combination of two or more antibodies of claim 72 comprising CBH-7 and CBH-4G.
76. The combination of two or more antibodies of claim 72 comprising CBH-7 and CBH-4D.
77. The combination of two or more antibodies of claim 72 comprising CBH-7 and CBH-17.
78. A virus displaying a combination of two antibodies directed to one or more conformational epitopes of E2 protein of Hepatitis C virus.
79. The virus of claim 78, wherein the antibodies comprise CBH-7 and CBH-4G.
80. The virus of claim 78, wherein the antibodies comprise CBH-7 and CBH-4D.
81. The virus of claim 78, wherein the antibodies comprise CBH-7 and CBH-17.

82. A pharmaceutical composition comprising the antibodies of claim 72, 73, 74, 75, 76, or 77 and a pharmaceutically acceptable excipient.
83. A method of treating a patient infected with HCV, the method comprising steps of:  
providing a patient infected with HCV or susceptible to HCV infection; and  
administering to the patient the antibodies of claim 73, 74, 75, 76, or 77.
84. A method of treating a patient exposed to HCV, the method comprising steps of:  
providing a patient exposed to HCV; and  
administering to the patient the antibody of claim 73, 74, 75, 76, or 77.
85. A vaccine comprising a peptide fragment of HCV E2 that contains epitopes recognized by the two or more antibodies of claim 72, 73, or 74.
86. A vaccine comprising a peptide fragment of HCV E2 that contains one or more epitopes recognized by two human monoclonal antibodies selected from the group consisting of CBH-7 and CBH-4D, CBH-7 and CBH-4G, or CBH-7 and CBH-17.
87. The vaccine of claim 85 further comprising an adjuvant.
88. The vaccine of claim 86 further comprising an adjuvant.--